FocalTherics, the Nasdaq listed American depositary share vehicle of the French societe anonyme EDAP TMS S.A., has spent the first half of 2026 executing one of the sharper strategic resets in the small cap medtech complex: a rebrand, the carve out of the two legacy cash businesses into held for sale status, a conversion from foreign private issuer to domestic filer, and a $45.7 million equity raise priced into the strength of the HIFU franchise. The argument in this report is that the stock is now a single asset: Focal One Robotic HIFU, a platform with genuine clinical differentiation and a fast growing installed base, wrapped around a capital structure that is expensive on paper but non threatening in cash terms.
The bull case is that the HIFU segment is inflecting. Revenue is compounding at high rates, gross margin is expanding with scale, Medicare payment is rising, and the clinical evidence base has matured from a single center story to a multi center randomized trial. The bear case is that the company is burning cash at a pace that only the August raise has contained, that the legacy businesses being sold are the only source of positive operating income, and that the warrant liability attached to the European Investment Bank credit facility converts every share price gain into a non cash accounting loss. The resolution of these tensions over the next two to three quarters, not the product story, decides the stock.
The company is organized as a French societe anonyme, headquartered in Vaulx en Velin, a suburb of Lyon, with a commercial operation that has historically spanned three businesses: high intensity focused ultrasound for urology, extracorporeal shock wave lithotripsy for kidney stones, and a distribution arm selling third party laser, imaging, and urodynamics products in Japan, South Korea, Malaysia, and Germany. Until 2025, the portfolio looked like a diversified urology platform. Full year 2025 revenue reached $70.5 million, with HIFU contributing roughly half of that total. ESWL added $7.5 million and Distribution added $25.7 million, and the two legacy segments together carried the positive operating income of the group. ESWL generated a small operating profit and Distribution roughly broke even, while HIFU posted a $20.7 million operating loss.
The strategic reset was executed in two steps in the spring of 2026: the board approved a plan to exit the two legacy segments on May 28, and the company announced the rebrand to FocalTherics the following day. This was not a cosmetic change, and the mechanism matters because it changes what shareholders are paying for. The ESWL and Distribution businesses represented roughly 47% of consolidated revenue in 2025, and their removal reclassifies the company as a single segment, single indication, single platform business. Before the reset, the multiple applied to a diversified urology company whose HIFU losses were subsidized by stable legacy cash flows. After the reset, the multiple applies to a pre commercial inflection device company whose entire earnings power sits in one product line and one geographic anchor market, the United States.
The concurrent loss of foreign private issuer status, effective January 1, 2026, completed the Americanization of the reporting. The company now files 10 K and 10 Q forms, is subject to domestic filer disclosure cadence, and the G&A step up visible in the half year results is largely the cost of that transition. The consequence for shareholders is a structurally higher cost base and a higher disclosure burden, but also a more familiar reporting framework for American institutional holders, a prerequisite for the index inclusion and coverage breadth that a sub $200 million market cap name needs to attract sustainable flows. The rebrand and the filer change are best read as a single act: FocalTherics is positioning itself to be priced as an American focal therapy pure play, not as a French diversified urology group.
The Focal One Robotic HIFU system is a cart based platform that integrates real time ultrasound imaging, MRI and biopsy map fusion through the HIFUsion software, a five axis sub millimeter robotic positioning system, and a dynamic focusing probe that delivers ablation energy while imaging simultaneously. The November 2025 FDA 510(k) clearance for the next generation Focal One system added advanced ultrasound imaging explicitly designed to support future artificial intelligence driven algorithms for tissue visualization and treatment evaluation. The CE Mark for prostate cancer dates to 2013, so this is a commercially established device with a multi decade regulatory history, not a first generation product seeking initial clearance.
The moat is evidentiary rather than patent based, though the patent portfolio provides a floor of 71 granted patents, covering core therapeutic ultrasound principles, system architecture, and planning software, some co owned with the French INSERM institute. The real barrier is the depth of independent clinical data, and the HIFI study, published in European Urology in late 2024, is the largest prospective comparative trial in the prostate cancer treatment literature. It enrolled 3,328 patients across 46 centers. It met the non inferiority primary endpoint of salvage treatment free survival against radical prostatectomy, with 90% versus 86%, a statistically significant advantage on urinary continence and erectile function. For a platform seeking to be priced as a category leader, that depth of independent, randomized, peer reviewed data is what no competitor in focal therapy can currently match.
The consequence of this evidence stack for shareholders is that Focal One sits in a different category than its competitors. The focal therapy market for prostate cancer is contested by cryoablation, irreversible electroporation, TULSA, and brachytherapy, and each of those has its own installation base and physician community. Focal One's claim to the category leadership position is the randomized data plus the reimbursement position. The Medicare physician fee schedule assigns the HIFU procedure the highest work RVU among the focal ablation options, and the proposed 2027 hospital outpatient payment for the HIFU code is $10,797, matching cryoablation. That payment represents a further 11.6% increase over the current year, the fourth consecutive annual reimbursement increase, and the payment structure is the mechanism through which the clinical evidence converts into hospital level business cases for new installations.
The platform expansion is the longer term thesis and carries the optionality. The company is advancing Focal One into benign prostatic hyperplasia, with international clinical studies underway and an approved American institutional review board, and into deep infiltrating endometriosis, where a CE Mark was received in March 2025 for posterior endometriosis infiltrating the rectum and surrounding structures, with the first commercial program launched at Toulouse University Hospital. The August investor presentation quantified the combined addressable market across prostate cancer, BPH, and endometriosis at more than 4.3 million procedures annually and a $10 billion revenue opportunity. The histotripsy program, a proprietary extension of the same platform toward non thermal ablation, remains in development. The significance of the multi indication architecture is that a single regulatory pathway, a single installation, and a single physician training program can be amortized across three disease areas, which is structurally different from competitors whose product is locked to one indication.
The first half of 2026, reported on a continuing operations basis, shows the inflection in the numbers. HIFU revenue reached $24.8 million for the six months, up 54.9% year over year. The company sold 24 Focal One systems, including 13 in the American market. Treatment driven revenue from revenue per procedure arrangements, leases, disposables, and services climbed 34.1% for the half. The second quarter alone produced record HIFU revenue of $13.2 million, up 38.8%. The repeat purchase pattern from those four systems indicates the commercial engine is compounding rather than churning, which is the single most important operational fact in the half year results.
The gross margin for the half reached 53.6%, driven by component cost reduction and fixed cost absorption at higher production volumes, while the second quarter printed 55.6%. The margin trajectory is the leading indicator of operating leverage, because the fixed cost base of the American sales organization has already been built and the revenue per procedure line compounds against it. Each additional point of margin flows disproportionately to the operating line as the revenue run rate climbs, and the installed base now stands at 184 units globally. The loss structure is the other half of the picture and it is where the capital structure question lives. The consolidated net loss for the first half was $23.6 million, widened from $13.9 million a year earlier. The operating loss on continuing operations was $16.1 million, a combination that looks worse than the cash trajectory. The warrant liability sat at $18.3 million in aggregate as of June 30, an artifact of the share price move rather than of any change in the underlying obligation.
The accounting artifact distorts the P and L, because the company is being penalized in reported earnings for its own share price appreciation, and the effect reverses when the share price falls. The cash reality is cleaner, with operating cash burn of $6.7 million for the half against a balance sheet that carried $21.5 million of cash before the August raise. The August offering reshapes the liquidity position. The company sold 8,425,000 ADSs at $4.75, the single largest equity raise in the company's history. The underwriters fully exercised their option for a further tranche, adding roughly $5.6 million of net proceeds on top of that initial amount. Shares outstanding rose by roughly 22% to 45,952,950, a dilution event that was the price of the runway. The raise was priced at a premium to the subsequent trading range, a data point about the underwriters' demand, and the post raise cash balance extends the runway well past 2027 on a current burn basis.
The debt stack is the item to monitor. The EIB finance contract of October 17 provides up to $36 million in three tranches for HIFU research and development. Tranche A drew in late 2025 at an effective interest rate of 21.63% on the debt component. Tranche B drew in April 2026 at 13.35%, a rate that reflects the warrant allocation rather than the coupon on the underlying borrowing. The economic cost of this capital is closer to the warrant dilution plus the coupon than the headline rate suggests, but it is real equity value transferred to the EIB in exchange for patient development funding that the company could not otherwise have accessed at this stage of the commercial cycle.
The near term execution question is the sale of the two legacy businesses. The company has classified ESWL and Distribution as held for sale, has initiated an active buyer program with confidentiality agreements executed and proposals in negotiation, and expects to complete one or more transactions within one year of the classification date, with no definitive agreement signed as of the quarterly report. The EIB credit facility contains provisions that disposal proceeds may be applied toward prepayment of outstanding borrowings, which means the sale proceeds are not automatically free cash for the HIFU business. The execution risk is threefold: the timing, the price realized relative to the carrying value of roughly $16.8 million of assets and $9.0 million of liabilities netted, and the transition arrangements that proposals contemplate, including employee transfers, customer support, electrode supply, and intellectual property licenses. A clean sale within the year at or above book would remove a drag, fund a portion of the EIB prepayment, and simplify the story. A drawn out process with disputes over distribution contracts or employee liabilities would keep management attention divided and keep the reported revenue base smaller than the legacy company's historical total.
The second execution variable is the American commercial ramp. The American market is now the anchor, having contributed 58% of HIFU revenue in the first half of 2026. That is a sharp reversal from the 37% the American market supplied in the same period of 2025. The revenue per procedure model, in which the company retains an economic interest per treatment rather than selling the system outright, is the mechanism that aligns hospital adoption with actual utilization, and the growth in treatment driven revenue is the leading indicator of whether the installed base is converting into procedure volume. The company's own figures show American procedure volume up 47% year over year in the second quarter. The risk is that the ramp is hospital network concentrated, so if adoption stalls among the next tier of health systems after the early adopters, the revenue per procedure line flattens even as new system sales continue, and the mix shifts back toward lumpy capital equipment revenue.
The third execution variable is the new indication pipeline, which is the difference between a single product company and a platform company. The BPH program has American IRB approval and parallel international studies, and the endometriosis program has both a CE Mark and a first commercial program in operation. These are genuine differentiators because they extend the same hardware into adjacent disease areas with different reimbursement streams, but they are also pre revenue: the endometriosis commercial launch in France is a small single site program, and the BPH program is in the clinical stage in the American market. The counterargument to the platform thesis is straightforward: Focal One's evidence base in prostate cancer is strong, but the company is asking shareholders to assign value to indication expansion that has not yet produced a single meaningful revenue dollar, and the regulatory path for a new indication on a cleared platform, while faster than de novo, still carries multi year timelines and clinical uncertainty. The honest framing is that BPH and endometriosis are optionality, not thesis.
The fourth variable is the warrant and debt mark. The EIB warrant liability grows with the share price, so the reported loss expands in exactly the quarters the stock performs well, which is a headwind to the narrative in the earnings materials even as the underlying business improves. The 90 day lock up on insider holdings from the August offering expired in mid November. The initial insider ownership statement filed in August 2026, together with the subsequent Form 4 filings, shows whether directors and officers are positioning to sell into the strength. The consequence for shareholders is that the P and L continues to be a poor proxy for operational trajectory, and the market's attention stays on revenue, gross margin, and operating loss on continuing operations, not on the bottom line.
The first and most specific downside scenario is that the legacy divestiture fails to close on acceptable terms within the year. The risk factors in the quarterly report are explicit that the discontinuation may take longer or cost more than expected, may result in disputes with customers, distributors, or employees, and may not produce the strategic benefits anticipated. The mechanism of harm is not the lost revenue, which is small at the consolidated level, but the working capital drag: the discontinued operations hold roughly $5.7 million of receivables and $4.5 million of inventory, plus the factored Japanese receivables tied to short term borrowings, and a prolonged sale process keeps that capital trapped and keeps the EIB prepayment question open. The share price reaction to a missed deadline or a below book sale would be disproportionate to the economic effect, which is how a small cap name de rates on a headline.
The second scenario is a commercial deceleration in the American market. The installed base is small in absolute terms, 184 systems globally, and the revenue per procedure line is still only about $20 million annualized. A pause in new health system adoption, whether from reimbursement push back, competitive action from the cryo and TULSA camps, or physician education friction, would show up as a flattening of treatment driven revenue within two to three quarters of the underlying cause, because the RPP model is a lagging utilization indicator. The consequence would be a margin compression spiral: the fixed cost base of the American sales organization, which drove selling and marketing expense to $13.8 million in the first half, does not scale down quickly, so a revenue deceleration hits operating leverage from the top. The historical base case is that the company survives on the $64 million cash pile, but the multiple would compress toward the low end of the range, and the dilution overhang from a follow on raise at a lower price would be the lasting damage.
The third scenario is the warrant mark becoming a self fulfilling narrative. The EIB warrants carry a put option that allows the EIB to demand a cash buy back at fair market value, capped at $23.5 million in aggregate. If the share price runs up on a strong year, the warrant liability balloons, the reported loss widens, and a market that reads only the bottom line could treat the accounting expense as an economic one, capping the multiple expansion. The counter to this scenario is that the warrant liability is non cash, matures in roughly two decades, and the put cap is a fraction of the post raise cash balance, so the economic threat is limited, but the optics are real for a stock being re rated from a French name to an American pure play, where every basis point of reported loss matters to the model builders.
The fourth scenario is concentration risk in the revenue base. No single customer represents more than 10% of revenue, which is the disclosed comfort, but the geographic concentration is the mirror image: the American market now generates the majority of HIFU revenue, and the reimbursement structure is a single payer system that sets prices by rule. A negative OPPS or physician fee schedule action on the HIFU code, or a re classification that lowers the facility payment, would hit the entire American book simultaneously, and the company has no other revenue stream to offset it. The proposed 2027 OPPS payment is a 11.6% increase, which is the current state of play, but the structure that delivers increases for four consecutive years is the same structure that could reverse. This is the asymmetry of the American focused model: the payment certainty is a moat in the base case and a single point of failure in the bear case.
The valuation framework has to start from the segment, because the consolidated P and L is no longer comparable to anything. The continuing operations business is HIFU, with first half revenue of $24.8 million, gross margin of 53.6%, and an operating loss that includes the domestic filer transition step up in G&A. Annualizing the first half at a modest growth adjustment gives a 2026 revenue run rate in the neighborhood of $55 million. That implies gross profit in the $30 million range and an operating loss that narrows but does not close as the legacy cost base is shed and the divestiture completes. The bear case assumes the American commercialization stalls at the current penetration, the divestiture closes below book, and the operating loss holds near $14 million annualized. In that world the company is a pre revenue inflection medtech with $64 million of cash and a revenue base growing in the mid teens, and the appropriate multiple is a low revenue multiple that values the cash and the installed base, implying an equity value in the mid to high $100 millions.
The base case assumes the American ramp continues at the second quarter pace, the divestiture closes near book within the year, and the operating loss narrows to roughly $8 million annualized by 2027. The HIFU revenue run rate passes $75 million and the margin expansion from component costs and absorption holds. At a 2x revenue multiple for a single platform medtech with growing but still negative operating leverage, plus the cash net of the EIB debt stack, the equity value sits in the $150 million to $190 million range, which is where the market is currently pricing the stock. This is the arithmetic of the current share price: the market is paying roughly a 2x forward revenue multiple for the HIFU segment with the cash pile effectively included, which is in line with, not generous to, comparable pre inflection device companies.
The bull case assumes the repeat purchase pattern continues, the BPH program reaches the American clinical stage with a readout, and the 2027 OPPS increase locks in the reimbursement growth. In that world the HIFU revenue run rate passes $100 million within two years, the operating loss converts to breakeven as the revenue per procedure line compounds against a fixed cost base that has already been built, and the platform optionality from BPH and endometriosis starts to be priced. The appropriate multiple for a company that has proven a commercial model and is crossing the revenue threshold where operating leverage inflects is 3x to 4x revenue, implying an equity value in the $300 million to $400 million range. The spread between the bear and the bull is the entire thesis, and it resolves on the revenue line, not on the product, because the product story is already in the price.
The multiple analysis has one structural caveat that the bear case underweights and the bull case overweights: the warrant liability is part of the capital structure and it grows with the valuation. In the bull scenario the EIB warrant liability approaches or exceeds its $23.5 million put cap, which is a fixed claim on equity value, and the effective dilution to existing holders is larger than the 22% from the August raise alone. The honest valuation is the revenue multiple applied to the continuing operations, plus cash, minus the EIB debt at amortized cost of roughly $18 million, minus the warrant liability at fair value, which in the current price environment sits near $18 million. The net of those three items is the number that sets the floor, and it is well above zero in all three scenarios, which is why the survival risk is low even though the earnings risk is high.
FocalTherics is no longer a question of whether Focal One is a good product. The HIFI study, the FARP randomized trial, the 510(k) clearance history, and the Medicare payment position have answered that question in the affirmative. The market has re rated the stock from a sub dollar French name to a mid single digit name on that evidence. The question now is whether the commercial execution matches the clinical evidence, and whether the capital structure, which is expensive in accounting terms but adequate in cash terms, holds through the two to three quarter window in which the divestiture closes and the American ramp either confirms or breaks. The judgment is that the base case is the likely outcome: the HIFU segment grows at high rates, the legacy businesses sell near book, the cash runway extends past 2027, and the operating loss narrows without closing. The stock at current levels is fairly valued for that outcome, which is a neutral to modestly constructive stance, not a recommendation, and the asymmetry runs to the bull side only if the BPH program produces an American readout that converts the platform optionality into a dated revenue stream.
The variables to track are narrow and legible. The first is the completion of the ESWL and Distribution sale and the treatment of the proceeds under the EIB prepayment clause, which is the single largest source of near term noise. The second is the American procedure volume growth rate in the revenue per procedure line, which is the leading indicator of the installed base converting into utilization. The third is the gross margin trajectory, which should keep expanding toward the low 60s as component costs fall and volumes rise, and any stall in that line is the first sign of the commercial model straining. The fourth is the warrant liability mark, which should be ignored in the operational read but watched in the capital structure, because the put cap is the one number that bounds the EIB's claim. The company has executed a clean strategic reset, funded itself through the inflection, and removed the legacy ballast. What remains is the binary the market is paying for: an American commercial ramp that compounds, or a stall that forces a re fundraise at a worse price. The balance of evidence, as of the first half of 2026, leans toward the former.